Prognostic Importance of the Soluble Form of IL-2 Receptor^|^alpha; (sIL-2R^|^alpha;) and its Relationship with Surface Expression of IL-2R^|^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases
| Autor: | Junko Hirato, Takeki Mitsui, Hirokazu Murakami, Hideki Uchiumi, Kohtaro Toyama, Norifumi Tsukamoto, Akio Saitoh, Hirotaka Nakahashi, Masaru Kojima, Yoko Hashimoto, Kayoko Murayama, Takahiro Jinbo, Hiromi Koiso, Yoshihisa Nojima, Hiroshi Handa, Morio Matsumoto, Takayuki Saitoh, Morio Sawamura, Masamitsu Karasawa, Akihiko Yokohama |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Performance status business.industry General Medicine CHOP medicine.disease Gastroenterology Lymphoma Regimen immune system diseases hemic and lymphatic diseases Internal medicine medicine Rituximab IL-2 receptor Risk factor business Diffuse large B-cell lymphoma medicine.drug |
| Zdroj: | Journal of Clinical and Experimental Hematopathology. 53:197-205 |
| ISSN: | 1880-9952 1346-4280 |
| DOI: | 10.3960/jslrt.53.197 |
| Popis: | We evaluated the prognostic significance of the serum level of the soluble form of interleukin-2 receptorα (sIL-2Rα) and investigated its association with CD25 expression on tumor cells in diffuse large B-cell lymphoma (DLBCL). Three hundred and thirty-eight adult patients with newly diagnosed DLBCL were eligible for this retrospective study. 32.2% of patients were treated with CHOP-like regimen and 67.8% with R-CHOP-like regimen. CD25 expression on the surface of tumor cells was evaluated in 143 cases and its relationship with sIL-2Rα level was also investigated. Both overall survival (OS) and progression-free survival (PFS) were poorer in patients with higher sIL-2Rα, in both R-CHOP and CHOP groups. sIL-2Rα > 1,000 U/mL and performance status (PS) ≥ 2 were independently associated with poorer OS, and sIL-2Rα > 1,000 U/mL, age > 60 years, and ≥ 2 extranodal sites were independently associated with poorer PFS in the R-CHOP group. The sIL-2Rα level was higher in the CD25-positive group than in the CD25-negative group in stage 3 or 4 disease (p = 0.010). Multiple linear regression analysis showed CD25 expression to be independently correlated with sIL-2Rα levels. High sIL-2Rα is an important risk factor for survival in DLBCL treated with not only CHOP-like, but also R-CHOP-like regimens, regardless of the tumor's expression of CD25. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|